BONTI, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2015-06-13
- Employees
- 1
- Market Cap
- -
- Website
- http://www.bonti.com
Study of EB-001 in Facial Scar Reduction
Phase 2
Completed
- Conditions
- Mohs Surgery
- Interventions
- Drug: EB-001Drug: 0.9% Sodium Chloride Injection
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Bonti, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03346902
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Study to Evaluate EB-001 in Reducing Musculoskeletal Pain
Phase 2
Completed
- Conditions
- Musculoskeletal Pain
- Interventions
- Drug: EB-001Drug: Placebo
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Bonti, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT03193593
- Locations
- 🇺🇸
Lotus Clinical Research, Pasadena, California, United States
Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
Phase 2
Completed
- Conditions
- Glabellar Frown Lines (GL)
- Interventions
- Drug: EB-001 injectionDrug: Placebo injection
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Bonti, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02939326
- Locations
- 🇺🇸
Center For Dermatology Clinical Research, Inc., Fremont, California, United States
🇺🇸Steve Yoelin, MD Medical Associates, INC., Newport Beach, California, United States
© Copyright 2025. All Rights Reserved by MedPath